المؤلفون: L. A. Knyazeva, L. I. Knyazeva, N. S. Meshcherina, I. I. Goryainov, M. A. Stepchenko, E. M. Khardikova, Л. А. Князева, Л. И. Князева, Н. С. Мещерина, И. И. Горяйнов, М. А. Степченко, Е. М. Хардикова

المصدر: Rheumatology Science and Practice; Vol 56, No 1 (2018); 41-47 ; Научно-практическая ревматология; Vol 56, No 1 (2018); 41-47 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20181

مصطلحات موضوعية: контурный анализ пульсовой волны, arterial stiffness, golimumab, intima-media thickness, common carotid artery, contour pulse wave analysis, артериальная ригидность, голимумаб, толщина комплекса интима–медиа, общая сонная артерия

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2498/1656; Alemao E, Cawston H, Bourhis F, et al. Cardiovascular risk factor management in patients with RA compared to matched non-RA patients. Rheumatology (Oxford). 2016 May;55(5):809-16. doi:10.1093/rheumatology/kev427; Meune C, Touze E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in RA: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis. 2010;103:253-61. doi:10.1016/j.acvd.2010.03.007; Горбунова ЮН, Новикова ДС, Попкова ТВ и др. Кардиоваскулярный риск у больных ранним ревматоидным артритом до назначения базисной противовоспалительной терапии (предварительные данные исследования РЕМАРКА). Научно-практическая ревматология. 2014;52(4):381-6 [Gorbunova YuN, Novikova DS, Popkova TV, et al. Cardiovascular risk in patients with early rheumatoid arthritis before disease-modifying antirheumatic therapy (preliminary data of the REMARCА study). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):381-6 (In Russ.)]. doi:10.14412/1995-4484-2014-381-386; Удачкина ЕВ, Новикова ДС, Попкова ТВ и др. Динамика липидных параметров крови у больных ранним ревматоидным артритом на фоне противоревматической терапии, проводимой по принципу «Лечение до достижения цели» (по данным 18-месячного наблюдения). Научнопрактическая ревматология. 2016;54(2):164-70 [Udachkina EV, Novikova DS, Popkova TV, et al. Time course of changes in blood lipid parameters in patients with early rheumatoid arthritis during treat-to-target antirheumatic therapy: According to 18-month follow-up findings. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(2):164-70 (In Russ.)]. doi:10.14412/1995-4484-2016-164-170; Попкова ТВ, Новикова ДС, Насонов ЕЛ. Сердечно-сосудистые заболевания при ревматоидном артрите: новые данные. Научно-практическая ревматология. 2016;54(2):122-8 [Popkova TV, Novikova DS, Nasonov EL. Cardiovascular diseases in rheumatoid arthritis: Latest data. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(2):1228 (In Russ.)]. doi:10.14412/1995-4484-2016-122-128; Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012 Mar;30(3):445-8. doi:10.1097/HJH.0b013e32834fa8b0; Laurent S, Cockcroft J, van Bortel LM, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588-605. doi:10.1093/eurheartj/ehl2542006; Vazquez-Del MM, Gomez-Banuelos E, Chavarria-Avila E, et al. Disease duration of rheumatoid arthritis is a predictor of vascular stiffness: a cross-sectional study in patients without known cardiovascular comorbidities: A STROBE-compliant article. Medicine (Baltimore). 2017 Aug;96(33):e7862. doi:10.1097/MD.0000000000007862; Ambrosino P, Lupoli R, Di Minno A, et al. Subclinical atherosclerosis in patients with rheumatoid arthritis. A meta-analysis of literature studies. Thromb Haemost. 2015 May;113(5):916-30. doi:10.1160/TH14-11-0921. Epub 2015 Feb 26.; Arida A, Zampeli E, Konstantonis G, et al. Rheumatoid arthritis is sufficient to cause atheromatosis but not arterial stiffness or hypertrophy in the absence of classical cardiovascular risk factors. Clin Rheumatol. 2015 May;34(5):853-9. doi:10.1007/s10067-0152914-1. Epub 2015 Mar 11.; Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med. 2008 Oct;121(10 Suppl 1):S21-31. doi:10.1016/j.amjmed.2008.06.014; Arida A, Protogerou AD, Konstantonis G, et al. Atherosclerosis is not accelerated in rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities. Rheumatology (Oxford). 2017 Jun 1;56(6):934-9. doi:10.1093/rheumatology/kew506; Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014 Mar;73(3):492-509. doi:10.1136/annrheumdis-2013-204573; Насонов ЕЛ. Фармакотерапия ревматоидного артрита: российские и международные рекомендации. Научнопрактическая ревматология. 2016;54(5):557-71 [Nasonov EL. Pharmacotherapy for rheumatoid arthritis: Russian and International guidelines. A pilot study. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):557-71 (In Russ.)]. doi:10.14412/1995-4484-2016557-571; Насонов ЕЛ, Мазуров ВИ, Каратеев ДЕ и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России» – 2014 (часть 1). Научно-практическая ревматология. 2014;52(5):477-94 [Nasonov EL, Mazurov VI, Karateev DE, et al. Spondyloarthritis: Evolution of a concept. Project: recommendations on treatment of rheumatoid arthritis developed by All-Russian Public organization «Association of Rheumatologists of Russia» – 2014 (part 1). NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):477-94 (In Russ.)]. doi:10.14412/1995-44842014-477-494; Westlake SL, Colebatch AN, Baird J, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2011,Mar;50(3):518-31. doi:10.1093/rheumatology/keq316; Mäki-Petäjä KM, Wilkinson IB. Anti-inflammatory drugs and statins for arterial stiffness reduction. Curr Pharm Des. 2009;15(3):290-303. doi:10.2174/138161209787354221; Князева ЛА, Мещерина НС. Влияние инфликсимаба на параметры ремоделирования артериального русла, уровень RANKL и остеопротегерина у больных ревматоидным артритом. Научно-практическая ревматология. 2013;51(6):666-70 [Knyazeva LA, Meshcherina NS. Effect of infliximab on parameters of remodeling of arterial bloodstream, RANKL and osteoprotegerin levels in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(6):666-70 (In Russ.)]. doi:10.14412/1995-4484-2013-666-70; Navarro-Millan I, Charles-Schoeman C, Yang S, et al. Changes in lipoproteins associated with treatment with methotrexate or combination therapy in early rheumatoid arthritis: results from the TEAR trial. Arthritis Rheum. 2013;65(6):1430-8. doi:10.1002/art.37916 12; Popa C, van den Hoogen FH, Radstake TR, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis. 2007 Nov;66(11):1503-7. doi:10.1136/ard.2006.066191; Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМАПРЕСС; 2013. 549 с. [Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological agents in the treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013. 549 p.].; Sandoo A, Hodson J, Douglas KM, et al. The association between functional and morphological assessments of endothelial function in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther. 2013;15(5):R107. doi:10.1186/ar4287; Kiortsis DN, Mavridis AK. Effects of infliximab lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheum Dis. 2006;33:4921-3.; Yun H, Xie F, Delzell E, et al. The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population. Br J Clin Pharmacol. 2015 Dec;80(6):1447-57. doi:10.1111/bcp.12709; Inzinger M, Wippel-Slupetzky K, Weger W, et al. Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria. Acta Derm Venereol. 2016 Feb;96(2):207-12. doi:10.2340/00015555-2214; Shealy DJ, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs. 2010 Jul-Aug;2(4):428-39. doi:10.4161/mabs.12304; Voulgari PV. Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. doi:10.1517/14728214.13.1.175; Чичасова НВ. Ингибитор фактора некроза опухоли α голимумаб в лечении ревматоидного артрита. Современная ревматология. 2014;(4):76-85 [Chichasova NV. The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2014;8(4):76-85 (In Russ.)]. doi:10.14412/1996-7012-2014-4-76-85; Кардиоваскулярная профилактика: национальные рекомендации. Кардиоваскулярная терапия и профилактика. 2011;10 (Прил. 2):64 [Cardiovascular prevention: national guidelines. Kardiovaskulyarnaya Terapiya i Profilaktika = Cardiovascular Therapy and Prevention. 2011;10 Suppl 2:64 (In Russ.)].; Kawasaki T, Sasayama S, Yagi S. Noninvаsive meаsurement of the age related changes in stiffness if major branches of the human arteries. Cardiovasc Res. 1987;144:345-52.; Парфенов АС. Экспресс-диагностика сердечно-сосудистых заболевавний. Мир измерений. 2008;(6):74-82. [Parfenov AS. Express diagnostics of cardiovascular zabolevaniy. Mir Izmerenii = World Measurements. 2008;(6):74-82 (In Russ.)].; Мельникова ЛВ. Значение гемодинамических факторов в развитии ремоделирования сосудов мышечноэластического типа при артериальной гипертензии. Саратовский научно-медицинский журнал. 2011;7(1):76-9 [Melnikova LV. Importance of hemodynamic factors in vascular remodeling of muscular elastic type in arterial hypertension. Saratovskii Nauchno-Meditsinskii Zhurnal = Saratov Journal of Medical Scientific Research. 2011;7(1):76-9. (In Russ.)].; Dalbeni A, Giollo A, Tagetti A, et al. Traditional cardiovascular risk factors or inflammation: Which factors accelerate atherosclerosis in arthritis patients? Int J Cardiol. 2017, Jan 14. pii: S0167-5273(16)33190-4. doi:10.1016/j.ijcard.2017.01.072. [Epub ahead of print].; Новикова ДС, Попкова ТВ, Кириллова ИГ и др. Оценка кардиоваскулярного риска у больных ранним ревматоидным артритом в рамках исследования РЕМАРКА (предварительные данные). Научно-практическая ревматология. 2015;53(1):24-31 [Novikova DS, Popkova TV, Kirillova IG, et al. Cardiovascular risk assessment in patients with early rheumatoid arthritis within the REMARCA study: Preliminary data. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(1):24-31 (In Russ.)]. doi:10.14412/1995-4484-2015-24-31; Van Sijl AM, Peters MJ, Knol DK, et al. Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum. 2011;40:389-97. doi:10.1016/ j.semarthrit.2010.06.006; Kirkham BW, Wasko MC, Hsia EC, et al. Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation. Ann Rheum Dis. 2014 Jan;73(1):161-9. doi:10.1136/annrheumdis-2012-202089; Bathon J, Wasko MC, Kirkham B, et al. Golimumab and cardiovascular disease: carotid artery ultrasound evaluation and cardiovascular adverse events. Ann Rheum Dis. 2010;69 (Suppl 3):464.; Wasko MC, Hsia EC, Kirkham B, et al. Effect of Golimumab on Carotid Atherosclerotic Disease Measures and Cardiovascular Events in Inflammatory Arthritides. J Clin Rheumatol. 2014 Jan;20(1):1-10. doi:10.1097/RHU.0000000000000053; https://rsp.mediar-press.net/rsp/article/view/2498

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2498
https://doi.org/10.14412/1995-4484-2018-41-47

المؤلفون: L. A. Knyazeva, N. Damjanov, L. I. Knyazeva, N. S. Meshcherina, I. I. Goryainov, Л. А. Князева, Н. Дамьянов, Л. И. Князева, Н. С. Мещерина, И. И. Горяйнов

المصدر: Rheumatology Science and Practice; Vol 56, No 3 (2018); 286-292 ; Научно-практическая ревматология; Vol 56, No 3 (2018); 286-292 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20183

مصطلحات موضوعية: RANKL, golimumab, pulse wave contour analysis, osteoprotegerin, rheumatoid arthritis, голимумаб, контурный анализ пульсовой волны, остеопротегерин, ревматоидный артрит

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2561/1708; Firesteinb GS. Evolving concepts of rheumatoid arthritis. Nature. 2003 May 15;423(6937):356-61. doi:10.1038/nature01661; Schett G, Hayer S, Zwerina J, et al. Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol. 2005 Nov;1(1):47-54. doi:10.1038/ncprheum0036; Alissa EM, Alnahdi WA, Alama N, et al. Bone mineral density and cardiovascular risk factors in postmenopausal women with coronary artery disease. Bonekey Rep. 2015 Nov 11;4:758. doi:10.1038/bonekey.2015.127; Ye C, Xu M, Wang S, et al. Decreased Bone Mineral Density Is an Independent Predictor for the Development of Atherosclerosis: A Systematic Review and Meta-Analysis. PLoS One. 2016 May 5;11(5):e0154740. doi:10.1371/journal.pone.0154740; Долженко АТ, Сагаловски С. Клеточно-молекулярные механизмы развития остеопороза: современные концепции и будущее направление терапии. Современная ревматология. 2016;10(2):56- 63 [Dolzhenko AT, Sagalovsky S. Cellular and molecular mechanisms of osteoporosis: current concepts and future direction treatment. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(2):56-63 (In Russ.)]. doi:10.14412/1996-7012-2016-2-56-63; Demer LL, Tintut J. Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008;117(22):2938-48. doi:10.1161/CIRCULATIONAHA.107.743161; Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S. Cathepsin cysteine proteases in cardiovascular disease. FASEB J. 2007;21(12):3029-41. doi:10.1096/fj.06-7924com; Langdahl BL. New treatment of osteoporosis. Osteoporos Sarcopenia. 2015;1(1):4-21. doi:10.1016/j.afos.2015.07.007; Periard D, Folly A, Meyer MA, et al. Aortic calcification and risk of osteoporotic fractures. Rev Med Suisse. 2010;6(271):2200-3 (In French).; Tabas I, Garcia-Cardena G, Owens GK. Recent insights into the cellular biology of atherosclerosis. J Cell Biol. 2015;209(1):13-22. doi:10.1083/jcb.201412052; Ndip A, Williams A, Jude EB, et al. The RANKL/RANK/ОПГ signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy. Diabetes. 2011 Aug;60(8):2187-96. doi:10.2337/db10-1220. Epub 2011 Jun 9.; Герштейн ЕС, Тимофеев ЮС, Зуев АА, Кушлинский НЕ. Лиганд-рецепторная система RANK/RANKL/ОПГ и ее роль при первичных новообразованиях костей (анализ литературы и собственные результаты). Успехи молекулярной онкологии. 2015:2(3);51-9 [Gershtein ES, Timofeev YuS, Zuev AA, Kushlinskii NE. RANK/RANKL/OPG ligand-receptor system and its role in primary bone neoplasms (literature analysis and own data). Uspekhi Molekulyarnoi Onkologii = Advances in Molecular Oncology. 2015;2(3):51-9 (In Russ.)]. doi:10.17650/2313-805X2015-2-3-51-59; Дыдыкина ПС, Дыдыкина ИС, Насонов ЕЛ. Влияние терапии генно-инженерными биологическими препаратами на костную ткань больных ревматоидным артритом. Научнопрактическая ревматология. 2014;52(6):669-77 [Dydykina PS, Dydykina IS, Nasonov EL. Impact of biological therapy on bone in patients with rheumatoid arthritis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2014;52(6):669-77 (In Russ.)]. doi:10.14412/1995-4484-2014-669-677; Vis M, Havaardsholm EA, Haugeberg G, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:1495-9. doi:10.1136/ard.2005.044198; Perpetuo IP, Caetano-Lopes J, Rodrigues AM, et al. Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis. Biomed Res Int. 2017;2017:2690402. doi:10.1155/2017/2690402; Aguilar Del Rey FJ, Garcia Portales R, Haro Liger M, et al. Effect of tumour necrosis factor α blockade on bone metabolism in chronic inflammatory joint diseases. Med Clin (Barc). 2016 Jul 15;147(2):56-62. doi:10.1016/j.medcli.2016.03.029; Князева ЛА, Мещерина НС. Влияние инфликсимаба на параметры ремоделирования артериального русла, уровень RANKL и остеопротегерина у больных ревматоидным артритом. Научно-практическая ревматология. 2013;51(6):666-70 [Knyazeva LA, Meshcherina NS. Effect of infliximab on parameters of remodeling of arterial bloodstream, RANKL and osteoprotegerin levels in patients with rheumatoid arthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(6):666-70 (In Russ.)]. doi:10.14412/1995-4484- 2013-666-70; Парфенов АС. Экспресс-диагностика сердечно-сосудистых заболеваний. Мир измерений. 2008;(6):74-82 [Parfenov AS. Express diagnostics of cardiovascular zabolevaniy. World Measurements. 2008;(6):74-82 (In Russ.)].; Van Tuyl LHD, Voskuyl AE, Boers M, et al. Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann Rheum Dis. 2010;69:1623-8. doi:10.1136/ard.2009.121764; Vik A, Mathiesen EB, Brox J, et al. Serum osteoprotegerin is a predictor for incident cardiovascular disease, and mortality in a general population: the Troms? Study. J Thromb Haemostatic. 2011;9(4):638-44. doi:10.1111/j.153 8- 7836.2011.04222.x; Van Compenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis. 2009;204(2):321-9. doi:10.1016/j.atherosclerosis.2008.09.033; Caidahl K, Ueland T, Aukrust P. Osteoprotegerin: a biomarker with many faces. Atheroscler Thromb Vasc Biol. 2010;30(9):1684-6. doi:10.1161/ATVBAHA.110.208843; Lieb W, Gona P, Larson MG, et al. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Artherioscler Thromb Vasc Biol. 2010;30(9):1849-54. doi:10.1161/ATVBAHA.109.199661; Townsend RR, Wilkinson IB, Schiffrin EL, et al. American Heart Association Council on Hypertension. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness. A Scientific Statement from the American Heart Association. J Hypertension. 2015;66(3):698-722. doi:10.1161/HYP.0000000000000033; Labovsky V, Vallone VB, Martinez LM, et al. Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derivated factor-1 and their receptors in epithelial metastatic breast cancer cell lines. Cancer Cell Internat. 2012;12(1):29. doi:10.1186/1475-2867-12-29; Nelson CA, Warren JT, Wang MW, et al. RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure. 2012;20(11):1971-82. doi:10.1016/j. str.2012.08.030; Kirkham BW, Wasko MC, Hsia EC, et al. Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation. Ann Rheum Dis. 2014 Jan;73(1):161-9. doi:10.1136/annrheumdis-2012-202089; Bathon J, Wasko MC, Kirkham B, et al. Golimumab and cardiovascular disease: carotid artery ultrasound evaluation and cardiovascular adverse events. Ann Rheum Dis. 2010;69 Suppl 3:464.; Wasko MC, Hsia EC, Kirkham B, et al. Effect of Golimumab on Carotid Atherosclerotic Disease Measures and Cardiovascular Events in Inflammatory Arthritides. J Clin Rheumatol. 2014 Jan;20(1):1-10. doi:10.1097/RHU.0000000000000053; https://rsp.mediar-press.net/rsp/article/view/2561

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2561
https://doi.org/10.14412/1995-4484-2018-286-292

المؤلفون: L. N. Denisov, E. S. Tsvetkova, G. Sh. Golubev, O. V. Bugrova, I. S. Dydykina, A. I. Dubikov, L. V. Menshikova, L. K. Peshekhonova, A. P. Rebrov, A. N. Torgashin, E. A. Trofimov, S. P. Yakupova, E. V. Zonova, O. Brewer, C. Cooper, J. Reginster, L. A. Knyazeva, Л. Н. Денисов, Е. С. Цветкова, Г. Ш. Голубев, О. В. Бугрова, И. С. Дыдыкина, А. И. Дубиков, Л. В. Меньшикова, Л. К. Пешехонова, А. П. Ребров, А. Н. Торгашин, Е. А. Трофимов, С. П. Якупова, Е. В. Зонова, О. Брюйер, С. Купер, Ж. Реджинстер, Л. А. Князева

المصدر: Rheumatology Science and Practice; Vol 54, No 6 (2016); 641-653 ; Научно-практическая ревматология; Vol 54, No 6 (2016); 641-653 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20166

مصطلحات موضوعية: симптоматические препараты замедленного действия для лечения остеоартрита, non-steroidal anti-inflammatory drugs, patented crystalline glucosamine sulfate, knee osteoarthritis, symptomatic slow-acting drugs for osteoarthritis, гиалуроновая кислота, нестероидные противовоспалительные препараты, запатентованный кристаллический глюкозамина сульфат

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2317/1522; https://rsp.mediar-press.net/rsp/article/view/2317/1535; Балабанова РМ, Эрдес ШФ. Динамика распространенности ревматических заболеваний, входящих в XIII класс МКБ-10, в популяции взрослого населения Российской Федерации за 2000–2010 гг. Научно-практическая ревматология. 2012;50(3):10-2 [Balabanova RM, Erdes Sh F. Trends in prevalence of rheumatic diseases in ICD-10 adult population of the Russian Federation over 2000-2010. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(3):10-2 (In Russ.)]. doi:10.14412/1995-4484-2012-702; Балабанова РМ, Эрдес ШФ. Распространенность ревматических заболеваний в России в 2012–2013 гг. Научно-практическая ревматология. 2015;53(2):120-4 [Balabanova RM, Erdes ShF. The incidence and prevalence of rheumatic diseases in Russia in 2012-2013. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(2):120-4 (In Russ.)]. doi:10.14412/1995-4484-2015-120-124; Фоломеева OM, Галушко ЕА, Эрдес ШФ. Распространенность ревматических заболеваний в популяциях взрослого населения России и США. Научно- практическая ревматология. 2008;46(4):4-13 [Folomeeva OM, Galushko EA, Erdes SF. Prevalence of rheumatic diseases in adult populations of Russian Federation and USA. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2008;46(4):4-13 (In Russ.)]. doi:10.14412/1995-4484-2008-529; Bruyere O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014;44(3):253-63. doi:10.1016/j.semarthrit.2014.05.014; Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145-55. doi:10.1136/ard.2003.011742; Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012;64(4):465-74. doi:10.1002/acr.21596; McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363-88. doi:10.1016/j.joca.2014.01.003; National Clinical Guideline Centre. Osteoarthritis care and management in adults: Methods, evidence and recommendations. London, UK: National Institute for Health and Care Excellence; 2014 February. Report No.: CG177.; Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010;18(4):476-99. doi:10.1016/j.joca.2010.01.013; Da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti- inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2016 May 21;387(10033):2093-105. doi:10.1016/S0140-6736(16)30002-2. Epub 2016 Mar 18.; Roberts E, Delgado Nunes V, Buckner S, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis. 2016;75(3):552-9. doi:10.1136/annrheumdis-2014-206914; Kahan A, Uebelhart D, de Vathaire F, et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two- year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60(2):524- 33. doi:10.1002/art.24255; Martel-Pelletier J, Pelletier JP. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis. 2010;2(2):95-104. doi:10.1177/1759720X09359104; Dougados M, Nguyen M, Berdah L, et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum. 2001;44(11):2539-47. doi:10.1002/1529-0131(200111)44:113.0.CO;2-T; Maheu E, Mazieres B, Valat JP, et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum. 1998;41(1):81-91. doi:10.1002/1529-0131(199801)41:13.0.CO;2-9; Pavelka K, Bruyere O, Cooper C, et al. Diacerein: benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO. Drugs Aging. 2016;33(2):75-85. doi:10.1007/s40266-016-0347-4; Fidelix TS, Macedo CR, Maxwell LJ, et al. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014;2:CD005117. doi:10.1002/14651858.cd005117.pub3; De Wan M, Volpi G, inventors; Rottapharm, assignee. Method of preparing mixed glucosamine salts. USA patent 5,847,107. 1998.; Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2009(2):CD002946.; Reginster JY. The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum. 2007;56(7):2105-10. doi:10.1002/art.22852; Eriksen P, Bartels EM, Altman RD, et al. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta- analysis of placebocontrolled trials. Arthritis Care Res (Hoboken). 2014;66(12):1844-55. doi:10.1002/acr.22376; Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357(9252):251-6. doi:10.1016/S0140-6736(00)03610-2; Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002;162(18):2113-23. doi:10.1001/archinte.162.18.2113; Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795-808. doi:10.1056/NEJMoa052771; Hochberg MC, Martel-Pelletier J, Monfort J, et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non- inferiority trial versus celecoxib. Ann Rheum Dis. 2016;75:37-44. doi:10.1136/annrheumdis- 2014-206792; Fransen M, Agaliotis M, Nairn L, et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo- controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015;74(5):851-8. doi:10.1136/annrheumdis- 2013-203954; Martel-Pelletier J, Roubille C, Abram F, et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis. 2015;74(3):547-56. doi:10.1136/annrheumdis-2013-203906; Persiani S, Rovati LC, Pastorini E, et al. Pharmacokinetics of glucosamine in man after oral administration of crystalline glucosamine sulfate or glucosamine hydrochloride alone or incombination with chondroitin sulfate. Osteoarthritis Cartilage. 2007;15(Suppl. C):C223. doi:10.1016/S1063-4584(07)62043-3; Altman RD. Glucosamine therapy for knee osteoarthritis: pharmacokinetic considerations. Expert Rev Clin Pharmacol. 2009;2(4):359-71. doi:10.1586/ecp.09.17; Bruyere O, Pavelka K, Rovati LC, et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage. 2008;16(2):254-60. doi:10.1016/j.joca.2007.06.011; Persiani S, Roda E, Rovati LC, et al. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage. 2005;13(12):1041-9. doi:10.1016/j.joca.2005.07.009; Jackson CG, Plaas AH, Sandy JD, et al. The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthritis Cartilage. 2010;18(3):297-302. doi:10.1016/j.joca.2009.10.013; Persiani S, Rotini R, Trisolino G, et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthritis Cartilage. 2007;15(7):764-72. doi:10.1016/j.joca.2007.01.019; Chiusaroli R, Piepoli T, Zanelli T, et al. Experimental pharmacology of glucosamine sulfate. Int J Rheumatol. 2011;2011:939265. doi:10.1155/2011/939265; Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo- controlled study using acetaminophen as a side comparator. Arthritis Rheum. 2007;56(2):555-67. doi:10.1002/art.22371; Bjordal JM, Ljunggren AE, Klovning A, et al. Non-steroidal antiinflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ. 2004;329(7478):1317. doi:10.1136/bmj.38273.626655.63; Altman RD, Abadie E, Avouac B, et al. Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. Osteoarthritis Cartilage. 2005;13(1):13-9. doi:10.1016/j.joca.2004.10.012; Cooper C, Adachi JD, Bardin T, et al. How to define responders in osteoarthritis. Curr Med Res Opin. 2013;29(6):719-29. doi:10.1185/03007995.2013.792793; Setnikar I, Rovati LC. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung. 2001;51(9):699-725.; Reichelt A, Forster KK, Fischer M, et al. Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. A randomised, placebo-controlled, double-blind study. Arzneimittelforschung. 1994;44(1):75-80.; Цветкова ЕС, Иониченок НГ, Денисов ЛН. Современная фармакотерапия остеоартроза коленных суставов: особенности симптоматического и болезнь-модифицирующего действия. Сообщение 1. Особенности симптоматического действия современных препаратов при остеоартрозе коленных суставов. Научно- практическая ревматология. 2015;53(1):63-8. [Tsvetkova ES, Ionichenok NG, Denisov LN. Current pharmacology for knee osteoarthritis: specific features of symptomatic and disease modifying effects. Communication 1. Specific features of the symptomatic effects of current drugs to treat knee osteoarthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(1):63-8 (In Russ.)]. doi:10.14412/1995-4484- 2015-63-68; Rovati LC, Girolami F, D’Amato M, et al. Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study. Semin Arthritis Rheum. 2016;45(4 Suppl.):S34-S41. doi:10.1016/j.semarthrit.2015.10.009; Scholtissen S, Bruyere O, Neuprez A, et al. Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. Int J Clin Pract. 2010;64(6):756- 62. doi:10.1111/j.1742-1241.2010.02362.x; Palma Dos Reis R, Giacovelli G, Girolami F, et al. Crystalline glucosamine sulfate in the treatment of osteoarthritis: evidence of long-term cardiovascular safety from clinical trials. Open Rheumatol J. 2011;5:69-77. doi:10.2174/1874312901105010069; Chou R, McDonagh MS, Nakamoto E, et al. Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review. October 2011. Rockville MD. Available from: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0016485/pdf/TOC.pdf. Last accessed June 1, 2016.; Lin J, Zhang W, Jones A, et al. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: metaanalysis of randomised controlled trials. BMJ. 2004;329(7461):324. doi:10.1136/bmj.38159.639028.7C; Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol. 2004;31(10):2002-12.; Simon LS, Grierson LM, Naseer Z, et al. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009;143(3):238-45. doi:10.1016/j.pain.2009.03.008; Цветкова ЕС, Панасюк ЕЮ, Иониченок НГ. Глюкозамин сульфат (дона) в терапии гонартроза: возможности и перспективы. Научно-практическая ревматология. 2004;42(2):7 [Tsvetkova ES, Panasyuk EY, Ionichenok NG. Glucosamine sulfate (Dona) in the treatment of gonarthrosis: possibilities and perspectives. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2004;42(2):7 (In Russ.)].; Pelster B. Osteoarthritis of the knee: percutaneous vs. oral treatment. In: Pelster B, editor. Topics in Arthritis and Rheumatism. Philadelphia: Lippincott-Raven; 1995. P. 9-12.; Underwood M, Ashby D, Cross P, et al. Advice to use topical or oral ibuprofen for chronic knee pain in older people: randomised controlled trial and patient preference study. BMJ. 2008;336(7636):138-42. doi:10.1136/bmj.39399.656331.25; Rechziegler H. Perkutane Therapie mit nicht-steroidalen Antiphlogistika. Therapiewoche. 1986;36:4674-83.; Walde HJ. Konzentration von Etofenamat in intra- und periartikulä ren Geweben nach perkutaner Applikation beim Menschen. Topische Behandlung mit nichtsteroidalen Antirheumatika. 4. Int. Etofenamat-Symposium vom 18.-21.6.1987 in Stresa, Italien: pmi-Verlag Frankfurt/Main: Der neue Weg; 1987. P. S91-4.; Pincus T, Koch G, Lei H, et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis. 2004;63(8):931-9. doi:10.1136/ard.2003.020313; Henry D, McGettigan P. Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. Int J Clin Pract Suppl. 2003;(135):43-9.; Garcia Rodriguez LA, Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal antiinflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. 2001;3(2):98-101. doi:10.1186/ar146; Chou CT, Tsai YY. A double-blind, randomized, controlled parallel group study evaluating the efficacy and safety of acemetacin for the management of osteoarthritis. Int J Clin Pharm Res. 2002;12(1):1-6.; Leeb BF, Bucsi L, Keszthelyi B. Behandlung der gonarthrose. Wirksamkeit und verträ glichkeit von retardiertem acemetacin im vergleich zu celecoxib. Orthopede. 2004;33:1032- 41.; Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12):1127-46. doi:10.1007/BF03261999; Freston JW. Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events. Am J Med. 1999;107(6A):78S-88S. doi:10.1016/S0002-9343(99)00371-X; Lipani JA, Poland M. Clinical update of the relative safety of nabumetone in long-term clinical trials. Inflammopharmacology. 1995;3:351-61. doi:10.1007/BF02668031; Singh G. Gastrointestinal complications of prescription and overthe-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther. 2000;7(2):115-21. doi:10.1097/00045391-200007020-00008; Hunt RH, Barkun AN, Baron D, et al. Recommendations for the appropriate use of anti- inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents. Can J Gastroenterol. 2002;16(4):231-40. doi:10.1155/2002/516092; Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a doubleblind, randomised trial. Lancet. 2007;369(9573):1621-6. doi:10.1016/S0140- 6736(07)60749-1; Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non- steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-79. doi:10.1016/S0140- 6736(13)60900-9; Olsen AM, Fosbol EL, Lindhardsen J, et al. Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: a nationwide cohort study. Circulation. 2012;126(16):1955-63. doi:10.1161/CIRCULATIONAHA.112.112607; Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006(2):CD005321. doi:10.1002/14651858.cd005321.pub2; Waddell DD, Bricker DC. Total knee replacement delayed with Hylan G-F 20 use in patients with grade IV osteoarthritis. J Manag Care Pharm. 2007;13(2):113-21. doi:10.18553/jmcp.2007.13.2.113; Mar J, Romero Jurado M, Arrospide A, et al. [Cost-analysis of viscosupplementation treatment with hyaluronic acid in candidate knee replacement patients with osteoarthritis]. Rev Esp Cir Ortop Traumatol. 2013;57(1):6-14 (In Span.). doi:10.1016/j.recot.2012.08.006; Altman R, Lim S, Steen RG, et al. Correction: Hyaluronic acid injections are associated with delay of total knee replacement surgery in patients with knee osteoarthritis: Evidence from a Large U.S. Health Claims Database. PLoS One. 2016;11(1):e0148591. doi:10.1371/journal.pone.0148591; Bannuru RR, Schmid CH, Kent DM, et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46-54. doi:10.7326/M14-1231; Bannuru RR, Vaysbrot EE, Sullivan MC, et al. Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;43(5):593-9. doi:10.1016/j.semarthrit.2013.10.002; Miller LE, Block JE. US-approved intra-articular hyaluronic acid injections are safe and effective in patients with knee osteoarthritis: Systematic review and meta-analysis of randomized, salinecontrolled trials. Clin Med Insights Arthritis Musculoskelet Disord. 2013;6:57-63.; Bannuru RR, Natov NS, Dasi UR, et al. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis – meta-analysis. Osteoarthritis Cartilage. 2011;19(6):611-9. doi:10.1016/j.joca.2010.09.014; Bannuru RR, Natov NS, Obadan IE, et al. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta- analysis. Arthritis Rheum. 2009;61(12):1704-11. doi:10.1002/art.24925; Karlsson J, Sjogren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology (Oxford). 2002;41(11):1240-8. doi:10.1093/rheumatology/41.11.1240; Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14(2):154-62. doi:10.1016/j.joca.2005.09.003; Juni P, Reichenbach S, Trelle S, et al. Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthritis Rheum. 2007;56(11):3610-9. doi:10.1002/art.23026; Pavelka K, Uebelhart D. Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinovial(R) vs hylan G-F20 [Synvisc(R)]) in the treatment of symptomatic knee osteoarthritis. A double-blind, controlled, randomized, parallel-group noninferiority study. Osteoarthritis Cartilage. 2011;19(11):1294-300. doi:10.1016/j.joca.2011.07.016; Maheu E, Zaim M, Appelboom T, et al. Comparative efficacy and safety of two different molecular weight (MW) hyaluronans F60027 and Hylan G-F20 in symptomatic osteoarthritis of the knee (KOA). Results of a non inferiority, prospective, randomized, controlled trial. Clin Exp Rheumatol. 2011;29(3):527-35.; Reichenbach S, Blank S, Rutjes AW, et al. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Rheum. 2007;57(8):1410-8. doi:10.1002/art.23103; Bagga H, Burkhardt D, Sambrook P, et al. Longterm effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol. 2006;33(5):946-50.; Ghosh P, Guidolin D. Potential mechanism of action of intraarticular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum. 2002;32(1):10-37. doi:10.1053/sarh.2002.33720; Pozo MA, Balazs EA, Belmonte C. Reduction of sensory responses to passive movements of inflamed knee joints by hylan, a hyaluronan derivative. Exp Brain Res. 1997;116(1):3-9. doi:10.1007/PL00005742; Smith MM, Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol Int. 1987;7(3):113- 22. doi:10.1007/BF00270463; Aviad AD, Houpt JB. The molecular weight of therapeutic hyaluronan (sodium hyaluronate): how significant is it? J Rheumatol. 1994;21(2):297-301.; Berenbaum F, Grifka J, Cazzaniga S, et al. A randomised, double-blind, controlled trial comparing two intra-articular hyaluronic acid preparations differing by their molecular weight in symptomatic knee osteoarthritis. Ann Rheum Dis. 2012;71(9):1454-60. doi:10.1136/annrheumdis-2011-200972; Голубев ГШ, Голубев ВГ, Евсеев ОА и др. Результаты клинического испытания нового протеза синовиальной жидкости GO-ON®. Травматология и ортопедия России. 2007;44(2):48-56 [Golubev G, Golubev V, Evseev O, et al. The results of clinical investigation of new synovial fluid prosthesis Go-On®. Travmatologiya i Ortopediya Rossii = Traumatology and Orthopedics of Russia. 2007;44(2):48-56 (In Russ.)].; Hochberg MC, Wohlreich M, Gaynor P, et al. Clinically relevant outcomes based on analysis of pooled data from 2 trials of duloxetine in patients with knee osteoarthritis. J Rheumatol. 2012;39(2):352-8. doi:10.3899/jrheum.110307; Risser RC, Hochberg MC, Gaynor PJ, et al. Responsiveness of the Intermittent and Constant Osteoarthritis Pain (ICOAP) scale in a trial of duloxetine for treatment of osteoarthritis knee pain. Osteoarthritis Cartilage. 2013;21(5):691-4. doi:10.1016/j.joca.2013.02.007; Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923. doi:10.2165/00003088-200443130-00004; Langley PC, Patkar AD, Boswell KA, et al. Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain. Curr Med Res Opin. 2010;26(1):239-51. doi:10.1185/03007990903426787; Gana TJ, Pascual ML, Fleming RR, et al. Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Med Res Opin. 2006;22(7):1391-401. doi:10.1185/030079906X115595; Cepeda MS, Camargo F, Zea C, et al. Tramadol for osteoarthritis. Cochrane Database Syst Rev. 2006(3):CD005522. doi:10.1002/14651858.cd005522.pub2; Roth SH. Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis. J Rheumatol. 1998;25(7):1358-63.; Raber M, Schulz HU, Schurer M, et al. Pharmacokinetic properties of tramadol sustained release capsules. 3rd communication: investigation of relative bioavailability under steady state conditions. Arzneimittelforschung. 1999;49(7):594-8.; Cnota PJ, Nowak H, Tagarro I, et al. Tramadol SR formulations: Pharmacokinetic comparison of a multiple-units dose (capsule) versus a single-unit dose (tablet). Clin Drug Investig. 2005;25(7):435-43. doi:10.2165/00044011-200525070-00002; Tagarro I, Herrera J, Barutell C, et al. Effect of a simple doseescalation schedule on tramadol tolerability : assessment in the clinical setting. Clin Drug Investig. 2005;25(1):23- 31. doi:10.2165/00044011-200525010-00003; Ethgen O, Bruyere O, Richy F, et al. Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am. 2004;86- A(5):963-74. doi:10.2106/00004623-200405000-00012; Griffin T, Rowden N, Morgan D, et al. Unicompartmental knee arthroplasty for the treatment of unicompartmental osteoarthritis: a systematic study. ANZ J Surg. 2007;77(4):214-21. doi:10.1111/j.1445-2197.2007.04021.x; Murray DW, Liddle AD, Dodd CA, et al. Unicompartmental knee arthroplasty: is the glass half full or half empty? Bone Joint J. 2015;97-B(10 Suppl A):3-8. doi:10.1302/0301-620X.97B10.36542; Lutzner J, Kasten P, Gunther KP, et al. Surgical options for patients with osteoarthritis of the knee. Nat Rev Rheumatol. 2009;5(6):309-16. doi:10.1038/nrrheum.2009.88; Sanders JO, Bozic KJ, Glassman SD, et al. Clinical practice guidelines: their use, misuse, and future directions. J Am Acad Orthop Surg. 2014;22(3):135-44. doi:10.5435/JAAOS-22- 03-135; Brouwer RW, Huizinga MR, Duivenvoorden T, et al. Osteotomy for treating knee osteoarthritis. Cochrane Database Syst Rev. 2014;12:CD004019. doi:10.1002/14651858.cd004019.pub4; Loveday D, Clifton R, Robinson A. Interventions for treating osteochondral defects of the talus in adults. Cochrane Database Syst Rev. 2010(8):CD008104. doi:10.1002/14651858.cd008104.pub2; Vasiliadis HS, Wasiak J. Autologous chondrocyte implantation for full thickness articular cartilage defects of the knee. Cochrane Database Syst Rev. 2010(10):CD003323. doi:10.1002/14651858.cd003323.pub3; Randsborg PH, Brinchmann J, Loken S, et al. Focal cartilage defects in the knee – a randomized controlled trial comparing autologous chondrocyte implantation with arthroscopic debridement. BMC Musculoskelet Disord. 2016;17(1):117. doi:10.1186/s12891-016-0969-z; Голубев ВШ, Кролевец ИВ, Жданов ВГ. Сравнительная характеристика методов лечения дефектов суставного хряща коленного сустава. New Medical Technologies. 2008:5. Доступно по ссылке: http://www.mst.ru/publications/rus/NewMedTechno_2008.pdf [Golubev GS, Kropevets IV, Zhdanov VG, et al. Comparative characteristics of methods of treatment of articular cartilage defects of the knee. New Medical Technologies. 2008:5. Available from: http://www.mst.ru/publications/rus/NewMedTechno_2008.pdf].; Голубев ГШ, Кролевец ИВ, Голубев ВГ. Сравнение эффективности малоинвазивных методов пластики дефектов суставного хряща коленного сустава. Доступно по ссылке: http://bone- surgery.ru/view/sravnenie_effektivnosti_maloinvazivnyh_metodov_plastiki_defektov_susta vnogo/ [Golubev G, Krolevetz I, Golubev V. Comparison of the effectiveness of minimally invasive methods of plastic surgery for defects in the articular cartilage of the knee joint. Available from: http://bonesurgery.ru/view/sravnenie_effektivnosti_maloinvazivnyh_metodov_plastiki_defektov_sustavnogo/].; Da Costa BR, Nuesch E, Kasteler R, et al. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev. 2014;9:CD003115. doi:10.1002/14651858.cd003115.pub4; https://rsp.mediar-press.net/rsp/article/view/2317

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2317
https://doi.org/10.14412/1995-4484-2016-641-653

المؤلفون: Larisa Aleksandrovna Knyazeva, N S Meshcherina, Л. А. Князева

المصدر: Rheumatology Science and Practice; Vol 51, No 6 (2013); 666-70 ; Научно-практическая ревматология; Vol 51, No 6 (2013); 666-70 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2013-6

مصطلحات موضوعية: остео- протегерин, rheumatoid arthritis, remodeling of cardiovascular bloodstream, RANKL, osteoprotegerin, ревматоидный артрит, ремоделирование сосудистого русла, RANКL

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1350/1010; https://rsp.mediar-press.net/rsp/article/view/1350

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/1350
https://doi.org/10.14412/1995-4484-2013-666-70

المؤلفون: L A Knyazeva, I I Goryaynov, E A Masalova, L I Knyazeva, A V Prasolov, LA Knyazeva, I I Goryainov, Л. А. Князева, И. И. Горяйнов, Е. А. Масалова, Л. И. Князева, А. В. Прасолов

المصدر: Modern Rheumatology Journal; Том 4, № 1 (2010); 39-40 ; Современная ревматология; Том 4, № 1 (2010); 39-40 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2010-1

مصطلحات موضوعية: Урисан, uric acid, Urisan, мочевая кислота

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/270/265; Ильина А.Е., Барскова В.Г. Применение урисана при подагре. Совр ревматол 2008;1:81-3. Ильина А.Е., Барскова В.Г. Как оптимизировать лечение больных подагрой с хроническим артритом. В фокусе - Урисан. Совр ревматол 2009;1:49-50. Ильина А.Е., Барскова В.Г. Значение диеты и биологически активных добавок к пище при подагре. Совр ревматол 2008;1:58-63. Frondoza C.G., Sohrabi A., Polotsky A. et al. An in vitro screening assay for inhibitors of proinflammatory mediators in herbal extracts using human synoviocyte cultures. In Vitro Cell Dev Biol Anim 2004;40:95-101. Do Monte F.H., dos Santos J.G., Russi M. et al. Antinociceptive and anti-inflammatory properties of the hydroalcoholic extract of stems from Equisetum arvense L. in mice. Pharmacol Res 2004;49(3):239-43. Yadav P.N., Liu Z., Rafi M.M. A diarylheptanoid from lesser galangal (Alpinia officinarum) inhibits proinflammatory mediators via inhibition of mitogen- activated protein kinase, p44/42, and transcription factor nuclear factor-kappa B. J Pharmacol Exp Ther 2003;305(3):925-31.; https://mrj.ima-press.net/mrj/article/view/270

الاتاحة: https://mrj.ima-press.net/mrj/article/view/270
https://doi.org/10.14412/1996-7012-2010-585

المؤلفون: G V Lukina, E L Nasonov, Ya A Sigidin, K Kh Kuzikyants, L. L. Bazevich, T I Zlobnna, R G Kamalova, L A Knyazeva, V I Mazurov, L V Men'shikova, A E Sizikov, E A Smirnova, N A Fofonova, T V Shabalina, L M Shkil', N V Yudina, S S Yakushin, Г. В. Лукина, Евгений Львович Насонов, Я. А. Сигидин, Л. А. Князева, В. И. Мазуров

المصدر: Rheumatology Science and Practice; Vol 46, No 1s (2008); 11-14 ; Научно-практическая ревматология; Vol 46, No 1s (2008); 11-14 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2008-1s

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/286/140; https://rsp.mediar-press.net/rsp/article/view/286

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/286
https://doi.org/10.14412/1995-4484-2008-2